A large share of medicines developed today may never reach patients for a surprisingly simple reason: they cannot dissolve well enough in water. For most treatments, the oral route remains the gold ...

Before Canada decides to rely on foreign drug regulators to approve new medicines, Health Canada needs to show that it will ...

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development process for industry and patients. Our two companies are applying AI in ...

Novo Nordisk's CagriSema could be a brand new growth driver for the company. Eli Lilly's orforglipron is breaking into a new, lucrative market. One of these companies should lead this market, but both ...

A new project seeking to transform the drug delivery process and take projects out of “the valley of death” between aspiration and accomplishment is getting help from La Jolla-based medical research ...

Less than six months after a series A fundraise, AI drug developer Chai Discovery has brewed up a $130 million series B to further energize development of its “computer-aided design suite” for new ...

Please provide your email address to receive an email when new articles are posted on . AIM-MASH AI Assist is the first AI drug development tool to be qualified by the FDA. The tool is designed to ...

The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their clinical trials. The agency gave a green light to the AI-Based Histologic ...

Two formative experiences shaped Craig Crews’ path into drug development. First, when he was still a child, his grandmother died from cancer at just 52 years old. “At the time, there weren’t very many ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

In our latest IPWatchdog Unleashed podcast, I spoke with Rob Sahr, shareholder at Wolf Greenfield and co-chair of our 2025 Life Sciences Masters™ program. Our conversation zeroed in on a hard truth ...

Profluent has raised $106 million to scale up use of its AI models for biology in drug development and agriculture. Ali Madani started thinking about how AI could be programmed for biology in 2020, ...